Cargando…

A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

BACKGROUND: Alpelisib in combination with cetuximab showed synergistic anti-tumour activity in head and neck squamous cell carcinoma (HNSCC) models. OBJECTIVES: The recommended phase 2 dose (RP2D) was determined in a phase 1b dose-escalation study. Phase 2 evaluated anti-tumour activity with a rando...

Descripción completa

Detalles Bibliográficos
Autores principales:	Razak, Albiruni R. Abdul, Wang, Hung-Ming, Chang, Jang-Yang, Ahn, Myung-Ju, Munster, Pamela, Blumenschein, George, Solomon, Benjamin, Lim, Darren Wan-Teck, Hong, Ruey-Long, Pfister, David, Saba, Nabil F., Lee, Se-Hoon, van Herpen, Carla, Quadt, Cornelia, Bootle, Douglas, Blumenstein, Lars, Demanse, David, Delord, Jean-Pierre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663259/ https://www.ncbi.nlm.nih.gov/pubmed/37875771 http://dx.doi.org/10.1007/s11523-023-00997-z

Ejemplares similares

Diabetic Ketoacidosis With Alpelisib
por: Jeun, Rebecca, et al.
Publicado: (2021)

Alpelisib for breast cancer
Publicado: (2022)

Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/− binimetinib or alpelisib
por: Huijberts, Sanne C. F. A., et al.
Publicado: (2020)

Alpelisib-Induced Diabetic Ketoacidosis
por: Espinosa, Luis Borges, et al.
Publicado: (2021)

Alpelisib-Induced Diabetic Ketoacidosis
por: Nguyen, Paul, et al.
Publicado: (2021)

Ketoacidosis in a Patient with Type 2 Diabetes Requiring Alpelisib: Learnings and Observations Regarding Alpelisib Initiation and Rechallenge
por: Leung, Mova, et al.
Publicado: (2022)

Bilateral Panuveitis and Exudative Retinal Detachments Associated with Alpelisib
por: Chong, Yu Jeat, et al.
Publicado: (2022)

Pharmacokinetics and Safety of Multiple-Dose Alpelisib in Participants with Moderate or Severe Hepatic Impairment: A Phase 1, Open-Label, Parallel Group Study
por: Marbury, Thomas, et al.
Publicado: (2023)

Phase I study of alpelisib (BYL719), an α‐specific PI3K inhibitor, in Japanese patients with advanced solid tumors
por: Ando, Yuichi, et al.
Publicado: (2019)

A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors
por: Rodon, Jordi, et al.
Publicado: (2018)

Alpelisib-Induced Diabetic Ketoacidosis- A Case Report
por: Rodriguez, Lisette Patricia, et al.
Publicado: (2021)

A Case of Diabetic Keto Acidosis From Alpelisib
por: Thumma, Soumya P, et al.
Publicado: (2021)

Alpelisib-Induced Hyperglycemia- A Small Case Series
por: Ekanayake, Preethika Subashini, et al.
Publicado: (2021)

Case report: Alpelisib-induced Stevens–Johnson syndrome
por: Kurian, Christine Jane, et al.
Publicado: (2022)

Beyond Skin Rash: Alpelisib-Induced Anaphylactic Reactions
por: Schutte, Tim, et al.
Publicado: (2023)

Alpelisib-Induced Diabetic Ketoacidosis in a Non-diabetic Patient
por: Fugere, Tyler, et al.
Publicado: (2021)

A multidisciplinary approach to optimizing care of patients treated with alpelisib
por: Rugo, Hope S., et al.
Publicado: (2021)

RF07 | PSUN359 Alpelisib-induced Diabetic Ketoacidosis
por: Majumdar, Sachin, et al.
Publicado: (2022)

Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)
por: Saba, Nabil F.
Publicado: (2017)

A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies
por: Tsang, Erica S., et al.
Publicado: (2022)

EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab
por: Kono, Scott A., et al.
Publicado: (2012)

A systematic review and meta-analysis of selected toxicity endpoints of alpelisib
por: Shields, Misty, et al.
Publicado: (2020)

Alpelisib-Induced Diabetic Ketoacidosis: A Case Report and Review of Literature
por: Carrillo, Maritza, et al.
Publicado: (2020)

Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma
por: Xu, Hongwei, et al.
Publicado: (2021)

Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer
por: Al Zeyoudi, Jawaher, et al.
Publicado: (2021)

Alpelisib-Induced Diabetes Mellitus: Case Report, Pharmacodynamics and Management Considerations
por: Pla Peris, Begoña, et al.
Publicado: (2022)

Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer
por: Abufaied, Mohamad, et al.
Publicado: (2021)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

Matrisomal genes in squamous cell carcinoma of head and neck influence tumor cell motility and response to cetuximab treatment
por: Goh, Kah Yee, et al.
Publicado: (2022)

Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data
por: Armaghani, Avan J, et al.
Publicado: (2020)

MON-678 Worsening Diabetes Control in Breast Cancer Patients Treated with Alpelisib
por: Geier, Robert, et al.
Publicado: (2020)

Tumor lysis Syndrome in a Patient with Metastatic Breast Cancer Treated with Alpelisib
por: Handy, Caitlin, et al.
Publicado: (2021)

Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib
por: Morin, Gabriel, et al.
Publicado: (2022)

THU259 Alpelisib-induced Diabetic Ketoacidosis: Call For A Multidisciplinary Approach
por: Kalara, Niketa, et al.
Publicado: (2023)

Acrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case report
por: Hinich, Maayan Geller, et al.
Publicado: (2023)

PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer
por: Kim, Kui-Jin, et al.
Publicado: (2020)

Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib
por: Batalini, Felipe, et al.
Publicado: (2020)

Navitoclax combined with Alpelisib effectively inhibits Merkel cell carcinoma cell growth in vitro
por: Chteinberg, Emil, et al.
Publicado: (2020)

Alpelisib Induced Hyperglycemic Ketoacidosis; Broadening the Adverse Effect Profile of an Emerging Cancer Therapy
por: Prasad, Apurwa, et al.
Publicado: (2021)

P1122: EFFICACY OF ALPELISIB IN PI3K-DRIVEN LANGERHANS CELL HISTIOCYTOSIS
por: Mazor, R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3u2uarhqbk7v0jp8l9pv9hb0m6